OKYO PHARMA LIMITED

Highlights OKYO Pharma Limited

Equities

EMMLD

GG00BMFG5F62

Market Closed - Nasdaq Other stock markets 21:30:00 06/06/2024 BST			5-day change	1st Jan Change
1.34 ^USD	+0.71%		-3.60%	-24.29%

03-22	H.C. Wainwright Adjusts Price Target on OKYO Pharma to $7 From $6, Maintains Buy Rating	MT
03-22	OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101	03-22	CI
OKYO Pharma Limited to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial	03-20	CI
OKYO Pharma Rising After FDA Approves Phase 2 Trial of Prospective Treatment for Cornea Eye Pain	02-09	MT
Okyo Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain	02-09	CI
OKYO Pharma Limited Reports Positive Safety and Efficacy Results in Its Phase 2, Randomized, Double-Masted, Placebo-Controlled Trial Evaluating the Safety and Efficacy of OK-101 Ophthalmic Solution in Patients with Dry Eye Disease	01-08	CI
Okyo Pharma Limited Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit	12-04	CI
Okyo Pharma Limited Announces Filing of an Investigational New Drug Application for Ok-101 to Treat Neuropathic Corneal Pain	09/10/23	CI
OKYO Pharma Limited Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease	05/10/23	CI
Okyo Pharma Limited Completes Enrollment in Phase 2 Clinical Trial of Ok-101 to Treat Dry Eye Disease	08/09/23	CI
OKYO Pharma Limited Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to Treat Dry Eye Disease	30/08/23	CI
OKYO Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2023	15/08/23	CI
OKYO Pharma Plans to Initiate Mid-Stage Trial in Neuropathic Corneal Pain; Shares Rise	28/07/23	MT
OKYO Pharma Limited Plans to Initiate Phase 2 Trial of Ok-101 in Neuropathic Corneal Pain	28/07/23	CI
OKYO Pharma Limited Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular Ok-101 for Dry Eye Disease	06/06/23	CI
OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease	22/12/22	CI
OKYO Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2022	15/08/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW